Advanced

SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas.

Magnusson, Kristina; de Wit, Meike; Brennan, Donal J; Johnson, Louis Banka LU ; McGee, Sharon F; Lundberg, Emma; Naicker, Kirsha; Klinger, Rut; Kampf, Caroline and Asplund, Anna, et al. (2011) In American Journal of Surgical Pathology 35(7). p.937-948
Abstract
The special AT-rich sequence-binding protein 2 (SATB2), a nuclear matrix-associated transcription factor and epigenetic regulator, was identified as a tissue type-specific protein when screening protein expression patterns in human normal and cancer tissues using an antibody-based proteomics approach. In this respect, the SATB2 protein shows a selective pattern of expression and, within cells of epithelial lineages, SATB2 expression is restricted to glandular cells lining the lower gastrointestinal tract. The expression of SATB2 protein is primarily preserved in cancer cells of colorectal origin, indicating that SATB2 could function as a clinically useful diagnostic marker to distinguish colorectal cancer (CRC) from other types of cancer.... (More)
The special AT-rich sequence-binding protein 2 (SATB2), a nuclear matrix-associated transcription factor and epigenetic regulator, was identified as a tissue type-specific protein when screening protein expression patterns in human normal and cancer tissues using an antibody-based proteomics approach. In this respect, the SATB2 protein shows a selective pattern of expression and, within cells of epithelial lineages, SATB2 expression is restricted to glandular cells lining the lower gastrointestinal tract. The expression of SATB2 protein is primarily preserved in cancer cells of colorectal origin, indicating that SATB2 could function as a clinically useful diagnostic marker to distinguish colorectal cancer (CRC) from other types of cancer. The aim of this study was to further explore and validate the specific expression pattern of SATB2 as a clinical biomarker and to compare SATB2 with the well-known cytokeratin 20 (CK20). Immunohistochemistry was used to analyze the extent of SATB2 expression in tissue microarrays with tumors from 9 independent cohorts of patients with primary and metastatic CRCs (n=1882). Our results show that SATB2 is a sensitive and highly specific marker for CRC with distinct positivity in 85% of all CRCs, and that SATB2 and/or CK20 was positive in 97% of CRCs. In conclusion, the specific expression of SATB2 in a large majority of CRCs suggests that SATB2 can be used as an important complementary tool for the differential diagnosis of carcinoma of unknown primary origin. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
American Journal of Surgical Pathology
volume
35
issue
7
pages
937 - 948
publisher
Lippincott Williams & Wilkins
external identifiers
  • wos:000291676200001
  • pmid:21677534
  • scopus:79959655409
ISSN
1532-0979
DOI
10.1097/PAS.0b013e31821c3dae
project
CREATE Health
language
English
LU publication?
yes
id
306522ae-7e63-455f-8813-2ce9f3017087 (old id 2008002)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21677534?dopt=Abstract
date added to LUP
2011-07-05 12:18:53
date last changed
2017-10-22 04:51:44
@article{306522ae-7e63-455f-8813-2ce9f3017087,
  abstract     = {The special AT-rich sequence-binding protein 2 (SATB2), a nuclear matrix-associated transcription factor and epigenetic regulator, was identified as a tissue type-specific protein when screening protein expression patterns in human normal and cancer tissues using an antibody-based proteomics approach. In this respect, the SATB2 protein shows a selective pattern of expression and, within cells of epithelial lineages, SATB2 expression is restricted to glandular cells lining the lower gastrointestinal tract. The expression of SATB2 protein is primarily preserved in cancer cells of colorectal origin, indicating that SATB2 could function as a clinically useful diagnostic marker to distinguish colorectal cancer (CRC) from other types of cancer. The aim of this study was to further explore and validate the specific expression pattern of SATB2 as a clinical biomarker and to compare SATB2 with the well-known cytokeratin 20 (CK20). Immunohistochemistry was used to analyze the extent of SATB2 expression in tissue microarrays with tumors from 9 independent cohorts of patients with primary and metastatic CRCs (n=1882). Our results show that SATB2 is a sensitive and highly specific marker for CRC with distinct positivity in 85% of all CRCs, and that SATB2 and/or CK20 was positive in 97% of CRCs. In conclusion, the specific expression of SATB2 in a large majority of CRCs suggests that SATB2 can be used as an important complementary tool for the differential diagnosis of carcinoma of unknown primary origin.},
  author       = {Magnusson, Kristina and de Wit, Meike and Brennan, Donal J and Johnson, Louis Banka and McGee, Sharon F and Lundberg, Emma and Naicker, Kirsha and Klinger, Rut and Kampf, Caroline and Asplund, Anna and Wester, Kenneth and Gry, Marcus and Bjartell, Anders and Gallagher, William M and Rexhepaj, Elton and Kilpinen, Sami and Kallioniemi, Olli-Pekka and Belt, Eric and Goos, Jeroen and Meijer, Gerrit and Birgisson, Helgi and Glimelius, Bengt and Borrebaeck, Carl and Navani, Sanjay and Uhlén, Mathias and O'Connor, Darran P and Jirström, Karin and Pontén, Fredrik},
  issn         = {1532-0979},
  language     = {eng},
  number       = {7},
  pages        = {937--948},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {American Journal of Surgical Pathology},
  title        = {SATB2 in Combination With Cytokeratin 20 Identifies Over 95% of all Colorectal Carcinomas.},
  url          = {http://dx.doi.org/10.1097/PAS.0b013e31821c3dae},
  volume       = {35},
  year         = {2011},
}